| Literature DB >> 23695021 |
H Arem1, M J Gunter, A J Cross, A R Hollenbeck, R Sinha.
Abstract
BACKGROUND: There are limited prospective studies of fish and meat intakes with risk of endometrial cancer and findings are inconsistent.Entities:
Mesh:
Year: 2013 PMID: 23695021 PMCID: PMC3738127 DOI: 10.1038/bjc.2013.252
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Distribution of selected endometrial cancer risk factors by quintile of red meat intake among women in the NIH-AARP Diet and Health Study (N=111 356 in baseline cohort, N=72 796 in risk factor cohort)
| 290 | 278 | 315 | 286 | 317 | |
| Daily red meat (g per 1000 kcal), mean (s.d.) | 7.1 (3.6) | 17.2 (2.5) | 25.9 (2.6) | 36.2 (3.6) | 58.5 (15.7) |
| Daily white meat (g per 1000 kcal), mean (s.d.) | 37.4 (34.3) | 36.1 (27.9) | 35.3 (24.6) | 35.2 (23.5) | 35.5 (23.1) |
| Daily processed meat (g per 1000 kcal), mean (s.d.) | 3.4 (6.0) | 5.5 (5.7) | 7.4 (6.2) | 9.8 (7.6) | 14.5 (12.0) |
| Age in years, mean (s.d.) | 61.8 (5.5) | 61.9 (5.5) | 61.8 (5.5) | 61.5 (5.5) | 61.1 (5.4) |
| Non- Hispanic White ( | 19 492 (87.5%) | 20 090 (90.2%) | 20 334 (91.3%) | 20 621 (92.6%) | 20 532 (92.2%) |
| Obese, BMI ⩾30 kg m–2 ( | 3148 (14.1%) | 4124 (18.5%) | 4819 (21.6%) | 5580 (25.1%) | 6721 (30.1%) |
| Ever use of hormone therapy ( | 9329 (41.9%) | 9307 (41.8%) | 9106 (40.9%) | 8763 (39.4%) | 7959 (35.7%) |
| Ever use of oral contraceptives ( | 8641 (38.8%) | 8815 (39.6%) | 8915 (40.0%) | 9131 (41.0%) | 9290 (41.7%) |
| Age at menarche ⩽10 years ( | 1408 (6.3%) | 1297 (5.8%) | 1360 (6.1%) | 1275 (5.7%) | 1492 (6.7%) |
| Age at first birth ⩾30 years ( | 1727 (7.8%) | 1574 (7.1%) | 1672 (7.5%) | 1561 (7.0%) | 1522 (6.8%) |
| Nulliparous ( | 4276 (19.2%) | 3907 (17.5%) | 3648 (16.4) | 3700 (16.6%) | 3751 (16.8%) |
| Age at menopause ⩾55 years ( | 2452 (11.0%) | 2332 (10.5%) | 2199 (9.9%) | 2169 (9.7%) | 2137 (9.6%) |
| Current smoker ( | 1790 (8.0%) | 2627 (11.8%) | 3128 (14.0%) | 3772 (16.9%) | 4548 (20.4%) |
| Physical exercise ⩾1 time per week ( | 16 101 (72.3%) | 15 000 (67.4%) | 14 019 (62.9%) | 13 147 (59.0%) | 11 770 (52.9%) |
| Energy (kcal day–1) | 1530 (630) | 1531 (623) | 1553 (631) | 1592 (645) | 1634 (681) |
| 194 | 191 | 214 | 187 | 209 | |
| DiMeIQx (ng per 1000 kcal day–1), mean (s.d.) | 0.24 (0.8) | 0.37 (0.8) | 0.49 (0.9) | 0.67 (1.2) | 1.1 (2.6) |
| MeIQx (ng per 1000 kcal day–1), mean (s.d.) | 2.2 (3.3) | 4.9 (6.1) | 7.3 (8.6) | 10.5 (12.7) | 18.4 (25.6) |
| PhIP (ng per 1000 kcal day–1), mean (s.d.) | 24.0 (63.8) | 31.3 (59.9) | 37.3 (60.1) | 47.2 (69.6) | 72.3 (106.2) |
| BaP (ng per 1000 kcal day–1), mean (s.d.) | 4.5 (11.7) | 7.5 (12.6) | 10.3 (14.9) | 14.4 (19.0) | 23.7 (34.4) |
Abbreviations: BaP=benzo(a)pyrene; BMI=body mass index; DiMeIQx=2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline; MeIQx=2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP=2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Associations between intake of fish, meat and meat mutagens with risk of endometrial cancer in the NIH-AARP Diet and Health Studya
| Model 1 | 281 | 1.00 | 270 | 0.88 (0.74–1.04) | 310 | 0.97 (0.82–1.14) | 279 | 0.84 (0.71–1.00) | 307 | 0.89 (0.75–1.05) | 0.293 |
| Model 2 | 271 | 1.00 | 265 | 0.90 (0.76–1.07) | 295 | 0.97 (0.82–1.14) | 271 | 0.85 (0.72–1.01) | 302 | 0.91 (0.77–1.08) | 0.450 |
| Model 1 | 260 | 1.00 | 284 | 1.05 (0.89–1.24) | 307 | 1.12 (0.95–1.32) | 313 | 1.14 (0.96–1.34) | 283 | 1.00 (0.85–1.19) | 0.955 |
| Model 2 | 249 | 1.00 | 281 | 1.07 (0.90–1.28) | 299 | 1.13 (0.96–1.34) | 305 | 1.14 (0.97–1.36) | 270 | 0.98 (0.83–1.17) | 0.660 |
| Model 1 | 269 | 1.00 | 272 | 0.94 (0.79–1.11) | 296 | 0.97 (0.82–1.15) | 281 | 0.89 (0.75–1.06) | 329 | 1.01 (0.85–1.19) | 0.660 |
| Model 2 | 255 | 1.00 | 268 | 0.97 (0.82–1.16) | 289 | 1.00 (0.84–1.19) | 273 | 0.91 (0.76–1.09) | 319 | 1.02 (0.86–1.21) | 0.695 |
| Model 1 | 280 | 1.00 | 280 | 0.99 (0.84–1.17) | 263 | 0.91 (0.77–1.08) | 310 | 1.09 (0.92–1.28) | 315 | 1.11 (0.94–1.30) | 0.059 |
| Model 2 | 269 | 1.00 | 274 | 1.01 (0.85–1.19) | 255 | 0.92 (0.77–1.09) | 304 | 1.11 (0.94–1.30) | 303 | 1.10 (0.93–1.29) | 0.095 |
| Model 1 | 455 | 1.00 | 99 | 0.93 (0.74–1.16) | 303 | 1.02 (0.88–1.17) | 273 | 0.89 (0.77–1.04) | 318 | 0.98 (0.85–1.13) | 0.797 |
| Model 2 | 444 | 1.00 | 96 | 0.94 (0.75–1.18) | 297 | 1.02 (0.88–1.18) | 263 | 0.90 (0.77–1.05) | 305 | 0.99 (0.85–1.15) | 0.914 |
| Model 1 | 174 | 1.00 | 212 | 1.17 (0.96–1.43) | 214 | 1.19 (0.97–1.45) | 176 | 0.96 (0.78–1.19) | 190 | 1.01 (0.82–1.25) | 0.286 |
| Model 2 | 170 | 1.00 | 207 | 1.17 (0.95–1.43) | 209 | 1.20 (0.98–1.47) | 167 | 0.95 (0.77–1.18) | 185 | 1.02 (0.82–1.26) | 0.303 |
| Model 1 | 179 | 1.00 | 183 | 1.00 (0.81–1.23) | 202 | 1.07 (0.87–1.30) | 212 | 1.08 (0.88–1.32) | 190 | 0.92 (0.75–1.14) | 0.321 |
| Model 2 | 169 | 1.00 | 182 | 1.06 (0.86–1.31) | 197 | 1.12 (0.91–1.38) | 207 | 1.13 (0.92–1.39) | 183 | 0.96 (0.77–1.18) | 0.346 |
| Model 1 | 353 | 1.00 | 10 | 0.89 (0.48–1.67) | 173 | 0.94 (0.79–1.13) | 202 | 1.05 (0.88–1.25) | 228 | 1.14 (0.96–1.35) | 0.066 |
| Model 2 | 342 | 1.00 | 9 | 0.84 (0.43–1.64) | 167 | 0.95 (0.79–1.14) | 198 | 1.07 (0.90–1.28) | 222 | 1.15 (0.97–1.37) | 0.049 |
| Model 1 | 165 | 1.00 | 221 | 1.28 (1.04–1.56) | 209 | 1.19 (0.97–1.46) | 204 | 1.18 (0.96–1.45) | 167 | 0.97 (0.78–1.20) | 0.060 |
| Model 2 | 160 | 1.00 | 212 | 1.27 (1.04–1.56) | 206 | 1.22 (0.99–1.50) | 200 | 1.22 (0.99–1.50) | 160 | 0.98 (0.79–1.22) | 0.084 |
Abbreviations: BaP=benzo(a)pyrene; CI=confidence interval; DiMeIQx=2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline; HR=hazard ratio; HT=hormone therapy; MeIQx=2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP=2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Model 1 was adjusted for age (<55, 55–59, 60–64, 65–69 or ⩾70 years); Body mass index (<18.5, 18.5-<25, 25-<30, ⩾30 kg m–2); smoking status (never, former, current); continuous total energy intake and was mutually adjusted for other meat intake. Model 2 was additionally adjusted age at menarche (⩽10, 11-12, ⩾13 years), age at first child's birth(<20, 20–29, ⩾30 years), parity (nulliparous, 1-2 children, ⩾3 children), age at menopause (still menstruating, <44, 44–49, 50–54, ⩾55 years), HT use (never, ever), oral contraceptive use (never, ever), diabetes (yes, no) and physical activity (never/rarely, 1–3 times per month, ⩾1 time per week).